Global Cephalosporin Market – Industry Trends and Forecast to 2029

Global Cephalosporin Market, By Type (First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporin, Fifth-Generation Cephalosporins, Others), Indication (Skin Infection, Urinary Tract Infections, Strep Throat, Ear Infections, Pneumonia, Sinus Infections, Meningitis, Gonorrhoea, Others), Drug Type (Branded, Generics), Dosage Form (Tablets, Capsules, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029

Cephalosporin Market Analysis and Size

The global cephalosporin market is expected to witness significant growth during the forecast period. The factors driving this market's growth are emerging markets and massive investment in research and development. The growth of the cephalosporin market enhanced by the growing cases of respiratory tract infections and increase research and development activities. Furthermore, advancements in treatment options and the presence of well-established healthcare facilities are some of the factors influencing cephalosporin demand. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global cephalosporin market in the forecast period 2022-2029. The expected CAGR of global antidotes market is tend to be around 3.10% in the mentioned forecast period. The market was valued at USD 14.55 billion in 2021, and it would grow upto USD 18.58 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Cephalosporin antibiotics are beta-lactam antibiotics that work in the same way that penicillin does. These antibiotics with a broad spectrum of action are used to treat bacterial infections such as pneumonia, kidney infections, bone infections, meningitis, and sexually transmitted diseases (STDs). Cephalosporin medicines come in five generations, each with a slightly different antibacterial range. These medications are also classified according to how they are administered, excreted, and absorbed, as well as how long the cephalosporin remains active in the body.  

Cephalosporin Market Scope and Segmentation

Global Cephalosporin Market Dynamics

Drivers

• Increase in Respiratory Tract Infections

The growing global prevalence of respiratory tract infections will drive industry growth. According to the 2017 Global Impact of Respiratory Disease report, lower respiratory tract infection and pneumonia are two of the leading causes of death, accounting for approximately 4 million deaths each year. In addition, pneumonia killed 920,136 children under the age of five in 2015, accounting for 15% of all deaths in this age group. Streptococcus pneumonia is still the most common bacterial cause of pneumonia in children under the age of five, affecting 393,000 children in 2015.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increasing Partnerships and Acquistions

The increased number of strategic partnerships is expected to open up new market growth opportunities. Various organisations around the world are working to improve antibiotic therapy development and delivery. One such programme is the Global Antibiotic Research and Development Partnership (GARDP), a non-profit research and development organisation founded by the Drugs for Neglected Disease Initiative (DNDi) and the World Health Organization (WHO). It focuses on expanding research and development of new antimicrobial diagnostics and agents through public-private partnerships. The formation of these partnerships is expected to aid the expansion of the cephalosporin market.

• Increasing Demand for Retail Pharmacies

The rise in the number of cephalosporins delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global cephalosporin market over a forecast period.

• High Cost

The huge expenditure associated with cephalosporins surely hamper the market growth.

This global cephalosporin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global cephalosporin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Cephalosporin Market        

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

The cephalosporin market is expected to improve in the post-pandemic era, as respective government bodies lift the enforced lockdown restrictions. Because of the wide range of applications they serve, various sectors are expected to recover quickly following the COVID-19 pandemic. As a result, the market is expected to level off in the near future.

Global Cephalosporin Market Scope

The global cephalosporin market is segmented on the basis of type, indication, drug type, dosage form, end user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• First-Generation Cephalosporins
• Second-Generation Cephalosporins
• Third-Generation Cephalosporins
• Fourth-Generation Cephalosporin
• Fifth-Generation Cephalosporins
• Others

Indication

• Skin Infection
• Urinary Tract Infections
• Strep Throat
• Ear Infections
• Pneumonia
• Sinus Infections
• Meningitis
• Gonorrhoea
• Others

Drug Type

• Branded
• Generics

Dosage Form

• Tablets
• Capsules
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Cephalosporin Market Regional Analysis/Insights

The global cephalosporin market is analysed and market size insights and trends are provided by type, indication, drug type, dosage form, end user, distribution channel as referenced above.

The major countries covered in the global cephalosporin market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for cephalosporin market throughout the forecasted period deu to the growing prevalence of diseases and rising healthcare expenditure, this will further propel the market's growth rate in this region.

Asia-Pacific dominates the market due surging level of disposable income in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Cephalosporin Market Share Analysis

The global cephalosporin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global cephalosporin market.

Key players operating in the global cephalosporin market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Aurobindo Pharma (India)
• Cipla Inc. (U.S.)
• Lannett (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Novo Nordisk A/S (Denmark)
• Currax Pharmaceuticals LLC (U.S.)
• Eisai Co., Ltd. (Japan)
• Takeda Pharmaceutical Company Limited (Japan)
• Merck & Co., Inc. (U.S.)